EUVIMEDEUVIMED entdecken
Crossref

Vitamin B6 Status in Hypophosphatasia: Association With Clinical Severity, Diagnostic Utility, and Effects on Vitamin B6 Metabolism by Supplementation and Enzyme Replacement Therapy

Tomoyuki Akiyama iD, Takuo Kubota, Kei Murayama, Makoto Fujiwara, Yasuhisa Ohata, Keiichi Ozono, Makiko Tajika, Keiko Ichimoto, Yohei Sugiyama, Mari Akiyama, Takashi Shibata, Hiroki Tsuchiya

Journal of Inherited Metabolic Disease · 2025

DOI: 10.1002/jimd.70036 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Inherited Metabolic Disease, 2025. Verfasst von Tomoyuki Akiyama und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. Hauptthemen laut MEDLINE: Hypophosphatasia, Vitamin B 6, Enzyme Replacement Therapy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science, Alexion Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study reports the concentrations of major vitamin B6 (VB6) vitamers (pyridoxal 5′‐phospate [PLP], pyridoxal [PL], and 4‐pyridoxic acid [PA]) in over 100 hypophosphatasia (HPP) cases to explore clues for clinical severity, to improve diagnostic sensitivity, and to examine VB6 changes by supplementation and enzyme replacement therapy. Serum samples were collected from HPP and non‐HPP patients. When available, cerebrospinal fluid (CSF) samples were also analyzed to determine PLP, PL, and PA concentrations. Serum PLP concentrations, PLP‐to‐PL ratios, and PLP‐to‐PA ratios were higher in untreated HPP patients compared to non‐HPP patients and reflected clinical severity. Perinatal severe HPP showed lower PL concentrations than perinatal benign HPP and the lowest PA concentrations among all clinical forms. Combining PLP‐to‐PL ratios with PLP concentrations improved diagnostic sensitivity. Under VB6 therapy, PLP concentrations and PLP‐to‐PL ratios remained higher in HPP patients than in non‐HPP patients. VB6 changes produced by ERT were most clearly reflected by the reduction of PLP‐to‐PL ratios. CSF PLP concentrations and PLP‐to‐PL ratios were higher in untreated HPP patients than in non‐HPP patients, while CSF PL concentrations were higher in patients on ERT compared to those not on ERT. Co‐evaluation of serum PLP, PL, and PA concentrations may help understand clinical severity, can improve diagnostic sensitivity, and can demonstrate the effect of ERT on VB6 metabolism more effectively than the assay of PLP concentrations alone. Altered VB6 status in the CSF suggests that tissue‐nonspecific alkaline phosphatase plays a key role in VB6 transport from peripheral blood to the brain via the blood–CSF barrier.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HypophosphatasiaVitamin B 6Enzyme Replacement TherapyHumansPyridoxal PhosphateFemaleMaleChildPyridoxic AcidAdultChild, PreschoolPyridoxalSeverity of Illness IndexAdolescentDietary SupplementsYoung AdultInfantMiddle Aged

Stichwörter der Autor:innen

4‐pyridoxic acidalkaline phosphatasebiomarkerphosphoethanolaminepyridoxal 5′‐phospatesensitivity

Substanzen

Vitamin B 6Pyridoxal PhosphatePyridoxic AcidPyridoxal

Autor:innen und Institutionen

  • Department of Pediatric Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
  • Department of Pediatrics, Osaka University Graduate School of Medicine, Osaka, Japan.
  • Department of Metabolism, Chiba Children's Hospital, Chiba, Japan.
  • Department of Pediatrics, Juntendo University Faculty of Medicine, Tokyo, Japan.
  • Diagnostics and Therapeutics of Intractable Diseases, Intractable Disease Research Center, Graduate School of Medicine, Juntendo University, Tokyo, Japan.
  • Center for Promoting Treatment of Intractable Diseases, ISEIKAI International General Hospital, Osaka, Japan.

ORCID-Profile: Tomoyuki Akiyama

Förderung

  • Japan Society for the Promotion of Science
  • Alexion Pharmaceuticals

Zitieren

APA

Akiyama, T., Kubota, T., Murayama, K., Fujiwara, M., Ohata, Y., Ozono, K., Tajika, M., Ichimoto, K., Sugiyama, Y., Akiyama, M., Shibata, T., & Tsuchiya, H. (2025). Vitamin B6 Status in Hypophosphatasia: Association With Clinical Severity, Diagnostic Utility, and Effects on Vitamin B6 Metabolism by Supplementation and Enzyme Replacement Therapy. Journal of Inherited Metabolic Disease. https://doi.org/10.1002/jimd.70036

Vancouver

Akiyama T, Kubota T, Murayama K, Fujiwara M, Ohata Y, Ozono K, et al. Vitamin B6 Status in Hypophosphatasia: Association With Clinical Severity, Diagnostic Utility, and Effects on Vitamin B6 Metabolism by Supplementation and Enzyme Replacement Therapy. Journal of Inherited Metabolic Disease. 2025. doi:10.1002/jimd.70036

BibTeX
@article{Akiyama2025,
  author = {Akiyama, Tomoyuki and Kubota, Takuo and Murayama, Kei and Fujiwara, Makoto and Ohata, Yasuhisa and Ozono, Keiichi and Tajika, Makiko and Ichimoto, Keiko and Sugiyama, Yohei and Akiyama, Mari and Shibata, Takashi and Tsuchiya, Hiroki},
  title = {Vitamin B6 Status in Hypophosphatasia: Association With Clinical Severity, Diagnostic Utility, and Effects on Vitamin B6 Metabolism by Supplementation and Enzyme Replacement Therapy},
  journal = {Journal of Inherited Metabolic Disease},
  year = {2025},
  doi = {10.1002/jimd.70036}
}
Kostenlos starten →